New pill for inflammation passes first safety check in healthy volunteers
NCT ID NCT07029568
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This early-stage study tested a new oral medicine, NNC0705-0001, in 116 healthy adults to see if it is safe and how the body processes it. The medicine aims to reduce chronic inflammation, which can lead to heart and kidney problems. Participants received either the medicine or a placebo, and the study lasted up to 41 days. Results will help decide if further testing is warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICON - location Groningen
Groningen, 9728 NZ, Netherlands
Conditions
Explore the condition pages connected to this study.